A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 16,800 shares of XENE stock, worth $643,608. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,800
Previous 31,800 47.17%
Holding current value
$643,608
Previous $1.24 Million 46.65%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$36.12 - $43.96 $1.67 Million - $2.03 Million
-46,222 Reduced 6.01%
722,504 $28.4 Million
Q2 2024

Aug 14, 2024

SELL
$36.25 - $43.75 $18.8 Million - $22.7 Million
-518,349 Reduced 40.27%
768,726 $30 Million
Q1 2024

May 15, 2024

BUY
$42.66 - $50.04 $863,054 - $1.01 Million
20,231 Added 1.6%
1,287,075 $55.4 Million
Q4 2023

Feb 14, 2024

BUY
$28.7 - $46.46 $15.6 Million - $25.2 Million
543,320 Added 75.09%
1,266,844 $58.4 Million
Q3 2023

Nov 14, 2023

BUY
$34.16 - $39.73 $7.6 Million - $8.84 Million
222,512 Added 44.41%
723,524 $24.7 Million
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $12.9 Million - $16.1 Million
-370,222 Reduced 42.49%
501,012 $19.3 Million
Q1 2023

May 15, 2023

SELL
$33.46 - $40.35 $9.81 Million - $11.8 Million
-293,173 Reduced 25.18%
871,234 $31.2 Million
Q4 2022

Feb 14, 2023

BUY
$33.06 - $39.43 $740,709 - $883,429
22,405 Added 1.96%
1,164,407 $45.9 Million
Q3 2022

Nov 14, 2022

SELL
$30.79 - $39.82 $15.6 Million - $20.2 Million
-506,037 Reduced 30.71%
1,142,002 $41.2 Million
Q2 2022

Aug 15, 2022

BUY
$25.44 - $35.16 $5.27 Million - $7.28 Million
206,959 Added 14.36%
1,648,039 $50.1 Million
Q1 2022

May 16, 2022

BUY
$25.09 - $33.13 $3.85 Million - $5.08 Million
153,277 Added 11.9%
1,441,080 $44.1 Million
Q4 2021

Feb 14, 2022

BUY
$15.6 - $35.4 $6.97 Million - $15.8 Million
446,587 Added 53.09%
1,287,803 $40.2 Million
Q3 2021

Nov 15, 2021

SELL
$14.86 - $19.45 $3.01 Million - $3.94 Million
-202,327 Reduced 19.39%
841,216 $12.9 Million
Q2 2021

Aug 16, 2021

BUY
$16.81 - $20.0 $13.8 Million - $16.4 Million
820,991 Added 368.9%
1,043,543 $19.4 Million
Q1 2021

May 17, 2021

BUY
$13.65 - $21.31 $2.06 Million - $3.22 Million
151,002 Added 211.04%
222,552 $3.98 Million
Q4 2020

Feb 16, 2021

SELL
$9.49 - $16.04 $2.28 Million - $3.85 Million
-240,132 Reduced 77.04%
71,550 $1.1 Million
Q3 2020

Nov 16, 2020

SELL
$10.82 - $13.35 $850,213 - $1.05 Million
-78,578 Reduced 20.13%
311,682 $3.45 Million
Q2 2020

Aug 14, 2020

SELL
$10.21 - $14.9 $1.18 Million - $1.72 Million
-115,769 Reduced 22.88%
390,260 $4.89 Million
Q1 2020

May 15, 2020

BUY
$8.08 - $17.57 $2.21 Million - $4.81 Million
273,764 Added 117.87%
506,029 $5.74 Million
Q4 2019

Feb 14, 2020

SELL
$8.11 - $14.65 $322,940 - $583,363
-39,820 Reduced 14.64%
232,265 $3.05 Million
Q3 2019

Nov 14, 2019

SELL
$8.74 - $10.51 $1.45 Million - $1.74 Million
-165,495 Reduced 37.82%
272,085 $2.45 Million
Q2 2019

Aug 14, 2019

SELL
$8.51 - $10.75 $1.82 Million - $2.31 Million
-214,443 Reduced 32.89%
437,580 $4.32 Million
Q1 2019

May 15, 2019

SELL
$6.39 - $10.42 $1.19 Million - $1.94 Million
-186,279 Reduced 22.22%
652,023 $0
Q4 2018

Feb 14, 2019

BUY
$5.61 - $12.62 $473,298 - $1.06 Million
84,367 Added 11.19%
838,302 $5.29 Million
Q3 2018

Nov 13, 2018

BUY
$9.0 - $14.9 $6.79 Million - $11.2 Million
753,935 New
753,935 $0

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.